Orion

Orion Debt

The Debt of Orion (271560.KS) as of Nov 13, 2026 is 69.89 B KRW. In the previous year, Debt was 229.67 B KRW — a change of -69.57% (lower).

Debt

69.89 BKRW

YoY

-69.57%

Last updated:

In 2021, Orion's total debt was 69.89 B KRW, a -69.57% change from the 229.67 B KRW total debt recorded in the previous year.

The Orion Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
599.74 B KRW
Jan 1, 2018
434.98 B KRW
Jan 1, 2019
286.76 B KRW
Jan 1, 2020
229.67 B KRW
Jan 1, 2021
69.89 B KRW
The Orion Debt history
YEARDebtYoY
69.89 BKRW-69.57%
229.67 BKRW-19.91%
286.76 BKRW-34.07%
434.98 BKRW-27.47%
599.74 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orion Stock analysis

What does Orion do? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases. As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life. Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma. The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas. In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells. Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier. In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol. Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals. Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland. In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide. In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion is one of the most popular companies on Eulerpool.

Debt Details

Understanding Orion's Debt Structure

Orion's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Orion's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Orion’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Orion’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Orion stock

Debt of Orion is 69.89 B KRW in 2021.

Debt of Orion changed from 229.67 B KRW to 69.89 B KRW, representing a -69.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Orion since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Orion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Orion

All Key Metrics — Orion